Cost–Effectiveness of Hepatitis C Virus Antiviral Treatment for Injection Drug User Populations
Hepatology2011Vol. 55(1), pp. 49–57
Citations Over TimeTop 1% of 2011 papers
Natasha K. Martin, Peter Vickerman, Alec Miners, Graham R. Foster, Sharon Hutchinson, David Goldberg, Matthew Hickman
Abstract
Despite the possibility of reinfection, the model suggests providing antiviral treatment to IDUs is the most cost-effective policy option in chronic prevalence scenarios less than 60%. Further research on how HCV treatment for injectors can be scaled up and its impact on prevalence is warranted.
Related Papers
- → Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era(2018)35 cited
- → Treatment of hepatitis C with interferon and ribavirin(2000)46 cited
- → Change in Viral Load during Antiviral Therapy Is Not Useful for the Prediction of Hearing Dysfunction in Symptomatic Congenital Cytomegalovirus Infection(2021)3 cited
- → Small Steps Toward a Better Treatment for Chronic Hepatitis C Infection: Mericitabine, Pegylated Interferon, and Ribavirin in the PROPEL and JUMP-C Trials(2013)2 cited
- Strategies to reduce the high cost of hepatitis C antiviral treatment: a literature review(2017)